Evofem Biosciences (EVFM) Investor presentation summary

Strategic focus and product portfolio

• Commercializing two FDA-approved products: a hormone-free contraceptive vaginal gel and a single-dose oral treatment for bacterial vaginosis and trichomoniasis.

• Hormone-free gel is the first and only on-demand prescription contraceptive of its kind, with net sales growing year-over-year since its 2020 U.S. launch.

• Oral granule product acquired in 2024, relaunching in the U.S. and targeting both BV and trichomoniasis.

• Both products are set for first international launches in the UAE in 2026.

• Targeting women seeking non-hormonal, on-demand, or single-dose solutions for sexual and reproductive health.

Market opportunity and growth

• U.S. contraceptive market valued at $8.8B in 2024, with 26.2M potential users for the hormone-free gel.

• Every 1% market share in the addressable market could generate $334M in annual net sales.

• GLP-1 user segment represents a $904M net sales opportunity for the hormone-free gel.

• Four consecutive years of annual net product sales growth, despite no marketing spend since Q4 2022.

• Expanding globally through exclusive agreements in the MENA region, starting with the UAE.

Product differentiation and patient targeting

• Hormone-free gel acts as a vaginal pH modulator, used only when needed, and can be combined with other contraceptives.

• Proven efficacy: 86% with typical use, 93% with perfect use, and no hormonal side effects.

• Targeting patients not using prescription contraceptives, postpartum mothers, those with depression, anxiety, or weight concerns, and cancer survivors.

• Strong social media and public campaigns, including the "Say Vagina" initiative, have increased brand awareness and engagement.

• Leading contraceptive brand presence on Instagram and among healthcare professionals.